Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 7/20 | 0.51 |
| ▸ | BRD4 | O60885 | 4/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE6A | P16499 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2447621 | 0.88 | CREBBP (0.49) | CREBBPBRD4PDE10AEP300TRPV1 | |
| SCHEMBL2449938 | 0.87 | CREBBP (0.50) | CREBBPBRD4PDE10APDE5APDE6A | |
| SCHEMBL2444491 | 0.86 | TRPV1 (0.37) | CREBBPBRD4PDE10APDE5APDE6A | |
| SCHEMBL2453296 | 0.84 | CREBBP (0.49) | CREBBPBRD4PDE10APDE5APDE6A | |
| SCHEMBL2449770 | 0.84 | CREBBP (0.49) | CREBBPBRD4PDE10APDE5APDE6A | |
| SCHEMBL2447273 | 0.81 | CREBBP (0.53) | CREBBPBRD4 | |
| SCHEMBL2447305 | 0.81 | CREBBP (0.53) | CREBBPBRD4EP300TRPV1 | |
| SCHEMBL2450613 | 0.81 | CREBBP (0.51) | CREBBPBRD4PDE10AEP300TRPV1 | |
| SCHEMBL2449067 | 0.81 | CREBBP (0.61) | CREBBPBRD4EP300 | |
| SCHEMBL2847158 | 0.80 | CREBBP (0.51) | CREBBPBRD4EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | claimed |
| EP-2367826-A1 | MODULATORS OF AMYLOID BETA. | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | claimed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | claimed |
| WO-2010053438-A1 | MODULATORS OF AMYLOID BETA. | ASTRAZENECA AB (SE) | 2010-05-14 | — | — | WO | claimed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| EP-2367826-A1 | MODULATORS OF AMYLOID BETA. | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| WO-2010053438-A1 | MODULATORS OF AMYLOID BETA. | ASTRAZENECA AB (SE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053438-A1 | MODULATORS OF AMYLOID BETA. | ASTRAZENECA AB (SE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | CREBBP 646/4885BRD4 1537/4885PDE10A 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.